© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 5, 388-394,
March 3, 1993
© 1993 Oxford University Press
Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results
Department of Medicine, University of Rochester Cancer Center Rochester, N.Y.
Department of Biostatistics, Dana-Farber Cancer Institute Boston, Mass
Department of Medicine, University of Pennsylvania Cancer Center Philadelphia
Department of Medicine, Medical College of Wisconsin Milwaukee
Department of Medicine, Tufts New England Medical Center Hospital Boston, Mass
Department of Medicine, Vanderbilt University Nashville, Tenn
Correspondence to:Alex. Y.Chang, M.D., 224 Alexander St., Oncology/Hematology Division, The Genesee Hospital, University of Rochester, Rochester, NY 14607.
Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents—taxol, merbarone, and piroxantrone—have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and toxicity of these agents in the treatment of stage IV metastatic non-small-cell lung cancer. Methods: Eligible patients (119) were randomly assigned to receive one of the three treatments given every 3 weeks: 250 mg/m2 taxol by a 24-hour intravenous infusion, 1000 mg/m2 merbarone by continuous intravenous infusion through a central catheter daily for 5 days, or 150 mg/m2 piroxantrone by intravenous infusion over 1 hour. Patients had received no chemotherapy. Response and toxicity were evaluated every 3 weeks. Results: Twenty-five patients were randomly assigned to receive taxol, 47 to receive merbarone, and 47 to receive piroxantrone. One of 44 assessable patients (2.3%) treated with piroxantrone had a complete response.
Rates for partial response were 20.8% (five of 24 patients) and 5.7% (two of 35) for assessable patients treated with taxol or merbarone, respectively. One-year survival rates were 41.7%, 21.6%, and 22.6%, and median survival times were 24.1, 19.9, and 29.3 weeks for taxol, merbarone, and piroxantrone, respectively. These differences were not statistically significant, but this study was not designed to compare survival. In general, toxicity was manageable. With premedication, no anaphylaxis was observed with taxol. The most common toxic effects were leukopenia with taxol or piroxantrone treatment and thromboembolic complications with merbarone. Death directly related to treatment occurred in 4% (one patient), 11.4% (four), and 5% (two) of the assessable patients receiving taxol, merbarone, and piroxantrone, respectively. Cardiotoxicity and neurotoxicity occurred only occasionally in all three arms. Conclusion: On the basis of the response rate (20.8% partial response) and 1-year survival rate (41.7%), taxol is an active agent for the treatment of metastatic non-small-cell lung cancer. Merbarone and piroxantrone are relatively inactive. Implications: Further study of taxol is warranted. In future studies, taxol should be combined with other agents, and granulocyte colony-stimulating factor should be used to ameliorate myelosuppression. [J Natl Cancer Inst 85: 388–394, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Matsubara, Y. Shimada, A. Takashima, D. Takahari, Y. Hirashima, N. T. Okita, T. E. Nakajima, K. Kato, T. Hamaguchi, Y. Yamada, et al. A Phase I Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., February 20, 2005; 23(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, P. Berthet, J. L. Breau, P. Lianes, M. Nicholson, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann. Onc., October 1, 2002; 13(10): 1539 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ogawara, M. Kawahara, S. Hosoe, S. Atagi, T. Kawaguchi, K. Okishio, N. Naka, T. Sunami, S. Mitsuoka, K. Inoue, et al. A Feasibility Study of Paclitaxel 225 mg/m2 and Carboplatin AUC = 6 in Untreated Advanced Non-small Cell Lung Cancer Patients in Japan Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax, January 1, 2002; 57(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Akiyama, Y. Ohe, T. Tamura, M. Sawada, A. Inoue, H. Kusaba, N. Yamamoto, I. Sekine, H. Kunitoh, T. Kodama, et al. A Dose Escalation Study of Paclitaxel and Carboplatin in Untreated Japanese Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kurata, T. Tamura, T. Shinkai, Y. Ohe, H. Kunitoh, T. Kodama, R. Kakinuma, T. Matsumoto, K. Kubota, H. Omatsu, et al. Phase I and Pharmacological Study of Paclitaxel Given Over 3 h with Cisplatin for Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., March 1, 2001; 31(3): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski, A. B. Sandler, L. L. Miller, P. K. Locker, C. K. Hanover, G. L. Elfring, V. K. Israel, N. Pirotta, and R. B. Natale Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2001; 19(4): 1078 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Perez-Soler, B. Kemp, Q. P. Wu, L. Mao, J. Gomez, A. Zeleniuch-Jacquotte, H. Yee, J. S. Lee, J. Jagirdar, and Y. H. Ling Response and Determinants of Sensitivity to Paclitaxel in Human Non-Small Cell Lung Cancer Tumors Heterotransplanted in Nude Mice Clin. Cancer Res., December 1, 2000; 6(12): 4932 - 4938. [Abstract] [Full Text]
|
|
|
|
|
|
U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al. Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3390 - 3399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Masuda, S. Negoro, S. Kudoh, T. Sugiura, K. Nakagawa, H. Saka, M. Takada, H. Niitani, and M. Fukuoka Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., August 16, 2000; 18(16): 2996 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Berthelot, B. P. Will, W. K. Evans, D. Coyle, C. C. Earle, and L. Bordeleau Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 16, 2000; 92(16): 1321 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Belani Combined Modality Therapy for Unresectable Stage III Non-Small Cell Lung Cancer : New Chemotherapy Combinations Chest, April 1, 2000; 117 (2009): 127S - 132S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer Chest, April 1, 2000; 117 (2009): 144S - 151S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Akerley III Paclitaxel in Advanced Non-Small Cell Lung Cancer : An Alternative High-Dose Weekly Schedule Chest, April 1, 2000; 117 (2009): 152S - 155S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, M. Jiroutek, and D. Johnson Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial J. Clin. Oncol., February 1, 2000; 18(3): 623 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer Oncologist, October 1, 1999; 4(5): 408 - 416. [Abstract] [Full Text]
|
|
|
|
|
|
G. Frasci, N. Panza, P. Comella, G. P. Nicolella, M. Natale, L. Manzione, D. Bilancia, R. Cioffi, L. Maiorino, G. De Cataldis, et al. Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase I-II Study J. Clin. Oncol., August 1, 1999; 17(8): 2316 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Monzo, R. Rosell, J. J. Sanchez, J. S. Lee, A. O'Brate, J. L. Gonzalez-Larriba, V. Alberola, J. C. Lorenzo, L. Nunez, J. Y. Ro, et al. Paclitaxel Resistance in Non-Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations J. Clin. Oncol., June 1, 1999; 17(6): 1786 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rowinsky, M. Jiroutek, P. Bonomi, D. Johnson, and S. D. Baker Paclitaxel Steady-State Plasma Concentration as a Determinant of Disease Outcome and Toxicity in Lung Cancer Patients Treated with Paclitaxel and Cisplatin Clin. Cancer Res., April 1, 1999; 5(4): 767 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al. Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial J. Clin. Oncol., March 1, 1999; 17(3): 914 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani, C. M. Kearns, E. G. Zuhowski, K. Erkmen, D. Hiponia, D. Zacharski, C. Engstrom, R. K. Ramanathan, M. J. Capozzoli, J. Aisner, et al. Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 676 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fortune and N. Osheroff Merbarone Inhibits the Catalytic Activity of Human Topoisomerase IIalpha by Blocking DNA Cleavage J. Biol. Chem., July 10, 1998; 273(28): 17643 - 17650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer and D. S. Ettinger The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy Oncologist, April 1, 1998; 3(2): 67 - 85. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. K. Rowinsky and R. C. Donehower Paclitaxel (Taxol) N. Engl. J. Med., April 13, 1995; 332(15): 1004 - 1014. [Full Text] [PDF]
|
|